PolyPid, Azurity Sign US$330M Deal for D-PLEX100

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Life science investors are taking note of a partnership between PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals aimed at bringing a new antibacterial drug to market, meant to prevent infection on abdominal surgical sites.

Key Takeaways

• PolyPid signed an exclusive deal with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada.
• Azurity will fund further clinical trials to potentially expand D-PLEX100's label beyond abdominal surgery, while PolyPid handles manufacturing and supply.
• The deal follows positive Phase 3 SHIELD II results, which hit the primary endpoint and showed a 60% relative risk reduction in infection incidence.
• A U.S. launch is targeted for the first quarter of 2027, with PolyPid retaining global rights outside the U.S. and Canada.

Azurity to Fund Further Trials for Antibiotic

On July 21, 2026, PolyPid announced that the company had entered into an agreement with Azurity for the commercialization of D-PLEX₁₀₀ — a drug intended to prevent surgical site infections — in both the U.S. and Canada. The agreement states that PolyPid will receive an upfront payment of US$15 million upon signing, with an additional US$15 million payable upon United States Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for the medication. Further, the company could earn up to US$300 million in additional regulatory, development, and sales-based milestone payments. As part of the collaboration, the companies may agree to jointly pursue potential label expansion of the drug into additional SSI (surgical site infections) to include more than abdominal sites.

Under the agreement, PolyPid will manufacture the drug, while Azurity will be responsible for commercial distribution.

Dikla Czaczkes Akselbrad, CEO of PolyPid, said in the release: " This partnership is a defining step in PolyPid's transition into a commercial-stage company, and Azurity is the right partner to bring D-PLEX₁₀₀ to U.S. and Canadian patients, hospitals, and surgeons. We believe that Azurity's first-in-class commercial model and demonstrated commercial execution will be invaluable in expanding access to D-PLEX₁₀₀, if approved. Importantly, this collaboration represents a meaningful validation of our unique platform, and allows us to fully realize the U.S. and Canadian commercial value of D-PLEX₁₀₀ while putting us in a position of financial strength to continue investing in our Kynatrix technology, pipeline, and the next generation of therapies."

For Azurity, CEO Ronald Scarboro said: "At Azurity, we believe meaningful innovation is measured by the difference a therapy makes in the realities of patient care. D-PLEX₁₀₀ is a differentiated therapy addressing an important unmet need, and we are excited to partner with PolyPid to help bring it to patients in the United States and Canada, if approved. Our commercial model was built to support specialized therapies like this — connecting the right treatment to the right healthcare professionals and patients through efficient, focused execution. Together, we believe we can expand access to an important new option while exploring opportunities to broaden its impact in the years ahead."PolyPid is an Israel-based biopharma company that focuses on developing long-acting, controlled-release drugs designed to address unmet medical needs across a diverse pipeline that includes surgical care, metabolic diseases, and more.

Pharma Funding Dipped, Still Historically Strong

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to approach four trillion defined daily doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Roth, Wainwright Issue "Buy" Ratings

Two separate analysts tackled Polypid's news after its release. On July 21, 2026, Boobalan Pachaiyappan, Ph.D., of Roth reiterated a "Buy" rating for the stock, with a price target of US$9.00. Regarding the exclusive commercialization and licensing partnership, Pachaiyappan wrote: "Is Azurity a right fit for PolyPid — we think yes! For context, Azurity is a specialty pharma with a proven hospital presence, given their focus on at least 10 therapeutic areas (including anti-infectives, which is where D-PLEX100 would fit in). Notably, D-PLEX100's de-risked Ph3 data in surgical site infections associated with colorectal cancer surgeries and first-in-class potential are squarely aligned with Azurity's business model, focusing on commercializing medicines in underserved patients."

On the same day, Brandon Folkes of H.C. Wainwright & Co. issued a "Buy" rating, with a price target of US$13.00. PolyPid's agreement with Azurity has helped put some of Folkes' concerns to rest, as he wrote: "The partnership removes a key uncertainty around the D-PLEX₁₀₀ commercial strategy. We have previously viewed a U.S. partnership as an important catalyst for PYPD, particularly given the longer institutional sales cycles that can accompany hospital products. PYPD had also been operating with a relatively limited cash runway, and we viewed a meaningful upfront payment as important to allowing the company to invest behind the broader pipeline without having to fund a U.S. commercial organization itself."

FDA Decision Expected Early 2027

The company expects the FDA to accept its NDA for D-PLEX₁₀₀ in August 2026.

According to PolyPid's investor presentation, the company hopes for a PDUFA date in early 2027 and expects to grow its Pipeline with Kynatrix, enabling expansion into additional high-value indications beyond the lead program.

Ownership & Share Information¹

PolyPid Ltd. has a market cap of US$77.71 million, with 19.17 million shares outstanding. The company's 52-week range is US$3.06-US$5.73. Institutions own 34.85% of shares, while Strategic Investors own 5.78%. Management & Insiders own 15.45% of shares, and the remaining 43.92% of shares are held by Retail.

Frequently Asked Questions

Q:  What is a Phase 3 clinical trial?

A: A Phase 3 clinical trial is one of the final stages of testing before a company asks regulators to approve a new medicine. It typically compares a new treatment with the current standard of care in a large group of patients to confirm that it is safe and effective.

Q:  What is a New Drug Application (NDA)?

A: A New Drug Application (NDA) is the formal request a pharmaceutical company submits to the U.S. Food and Drug Administration (FDA) asking for permission to sell a new drug. The FDA reviews the clinical trial data, manufacturing process, and safety information before deciding whether to approve the treatment.

Q:  What are surgical site infections?

A: Surgical site infections (SSIs) are infections that develop in the area of the body where surgery was performed. They can range from mild skin infections to more serious complications that require additional treatment, longer hospital stays, or even more surgery.

Q:  Why do biotech companies partner with larger pharmaceutical companies?

A: Many biotech companies specialize in discovering and developing new medicines, but don't have the resources to manufacture, market, and distribute them on a large scale. Partnering with an established pharmaceutical company allows a promising treatment to reach patients more efficiently while helping the biotech company fund future research.

Q:  What is a PDUFA date, and why do investors watch it?

A: A PDUFA date is the deadline by which the FDA aims to decide whether to approve a new drug after reviewing its application. Investors closely follow these dates because an approval can open the door to commercial sales, while a delay or rejection can significantly affect a company's outlook.